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ABSTRACT Testing of staphylococci other than Staphylococcus aureus (SOSA) for
mecA-mediated resistance is challenging. Isolates of Staphylococcus capitis, Staphylo-
coccus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri were evalu-
ated by cefoxitin and oxacillin broth microdilution (BMD), disk diffusion (DD), and
PBP2a immunoassay, and the results were compared to mecA PCR results. No phe-
notypic susceptibility test correlated well with PCR results across all species, al-
though the PBP2a immunoassay yielded 100% correlation. Oxacillin BMD testing by
current Clinical and Laboratory Standards Institute (CLSI) SOSA breakpoints led to
2.1% very major errors (VMEs) and 7.1% major errors (ME). Adjusting this breakpoint
up by a dilution (susceptible, 0.5 g/ml; resistant, 1.0 g/ml) led to 2.8% VMEs
and 0.3% MEs. Among species evaluated, S. haemolyticus had unacceptable VMEs
with this new breakpoint (6.4%), as did S. hominis (4.0%). MEs were acceptable by
this new breakpoint, ranging from 0 to 1.2%. Oxacillin DD yielded high ME rates
(20.7 to 21.7%) using CLSI or European Committee on Antimicrobial Susceptibility
Testing breakpoints. VMEs ranged from 0 to 5.3%. Cefoxitin BMD led to 4.9% VMEs
and 1.6% MEs. Cefoxitin DD performed best when interpreted with the CLSI SOSA
breakpoint, with 1.0% VMEs and 2.9% MEs. This study led CLSI to adjust the oxacillin
MIC breakpoints for SOSA. Laboratories should be aware that no individual pheno-
typic test correlates well across all species of SOSA with mecA PCR results. Molecular
testing for mecA or evaluation for PBP2a is the preferred approach.
KEYWORDS CLSI, EUCAST, PBP2a, Staphylococcus, breakpoint, broth microdilution,
cefoxitin, disk diffusion, mecA, minimum inhibitory concentration
Staphylococci other than Staphylococcus aureus (SOSA [traditionally referred to asthe coagulase-negative staphylococci, although not all are technically coagulase
negative]) are normal microbiota of the human skin and mucosal surfaces and impor-
tant opportunistic pathogens, associated predominantly with infection in the setting of
indwelling/implanted foreign bodies and devices (1). Forty-six validly described species
and 24 subspecies are members of this broad group— unified by their negative
coagulase reaction (2–6). One species, Staphylococcus schleiferi, includes both free
(tube) coagulase-negative and -positive subspecies, S. schleiferi subsp. schleiferi and S.
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schleiferi subsp. coagulans, respectively (2). Historically, identification of SOSA to the
species level by morphological and biochemical testing was difficult, lacked resolution,
and was often deemed unnecessary as these were commonly viewed as nonpathogenic
contaminants (1). In recent years, identification of the members of the SOSA has
become more commonplace, through both a better understanding of their role as
opportunistic pathogens (1) and the availability of matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS) in clinical laboratories (7).
The ability to accurately identify SOSA to the species level has improved understanding
of the clinical significance of specific species and is accompanied by a need to
understand how to best evaluate these isolates for the presence of mecA and ultimately
susceptibility to -lactams.
Accurate detection of mecA (or mecC)-mediated resistance to the penicillinase-stable
penicillins (oxacillin, nafcillin, cloxacillin, dicloxacillin, and flucloxacillin) is challenging
for the staphylococci due to the heterogenous nature of mecA expression across this
diverse group of bacteria. In 2000, the Clinical and Laboratory Standards Institute (CLSI
[then the National Committee for Clinical Laboratory Standards]) first adopted SOSA
oxacillin breakpoints that differed from those used for Staphylococcus aureus. This study
was conducted using 50 isolates, weighted heavily for isolates of Staphylococcus
epidermidis (n  27). Eight isolates of Staphylococcus hominis, 6 of Staphylococcus
warneri, 3 of Staphylococcus haemolyticus, 2 each of Staphylococcus lugdunensis and
Staphylococcus saprophyticus, and a single isolate each of Staphylococcus capitis and
Staphylococcus simulans were also evaluated (8). In this study, good correlation (84 to
94%) between oxacillin MIC values of 0.25 g/ml and the absence of mecA was found
for all isolates. Similarly, excellent correlation (99 to 100%) between oxacillin MICs of
0.5 g/ml and the presence of mecA was found for S. epidermidis. However, poor
correlation between oxacillin MICs of 0.5 g/ml and the presence of mecA was shown
for species other than S. epidermidis, ranging from 53.0 to 66.4% correlation (i.e., 33.6
to 47.0% major errors [MEs]). In 2004, CLSI recommended cefoxitin, a cephamycin, be
used as a surrogate test for oxacillin as it was found that cefoxitin disk results correlated
better with the presence of mecA for SOSA, particularly isolates with MIC values in the
0.5- to 2.0-g/ml range (9).
In 2016, CLSI formed a coagulase-negative Staphylococcus ad hoc working group to
evaluate existing oxacillin and cefoxitin testing recommendations to determine their
performance as surrogate tests for mecA/C in staphylococci other than S. aureus and S.
lugdunensis (referred to herein as SOSA for simplicity). Prioritization of species evalu-
ated include those with known or suspected testing challenges (e.g., Staphylococcus
pseudintermedius) and those with a higher prevalence in human infections (e.g., S.
epidermidis). The combined work has led to several changes to recommendations in the
M100 standard for these isolates (Table 1), including addition of oxacillin disk break-
points for Staphylococcus pseudintermedius (10), S. schleiferi (11), and S. epidermidis (12)
TABLE 1 Overview of CLSI updates to staphylococcal testing recommendations to predict the presence of mecA
Year Species Recommendation(s) Reference
1986 All staphylococci Publication of methicillin, nafcillin, and oxacillin MIC and DD susceptibility criteria in M100, first
informational supplement
26
1999 SOSA Establishment of oxacillin MIC and DD breakpoints in M100 that are different than those for S. aureus 8
1999 All staphylococci Deletion of methicillin MIC and DD susceptibility criteria—recommendation to test oxacillin alone 8
2004 S. aureus SOSA Introduction of the cefoxitin disk diffusion test to predict oxacillin resistance 9
2005 S. lugdunensis Inclusion of S. lugdunensis with S. aureus oxacillin and cefoxitin breakpoints 9
2006 S. lugdunensis Warning that cefoxitin and not oxacillin should be used for disk diffusion of S. lugdunensis 9
2012 S. aureus Deletion of oxacillin disk breakpoints 9
2012 SOSA Recommendation to perform cefoxitin disk, PBP2a, or mecA test if oxacillin MIC of 0.5–2.0 g/ml
for species other than S. epidermidis
9
2014 S. pseudintermedius Publication of oxacillin MIC and disk breakpoints; warning against use of cefoxitin tests for this species 10
2015 S. schleiferi Publication of oxacillin MIC and disk breakpoints; warning against use of cefoxitin for this species 11
2018 S. epidermidis Addition of oxacillin disk test for S. epidermidis, confirmation of MIC breakpoint 12
2021 SOSA Oxacillin breakpoint updated This work
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and recommendation against use of cefoxitin to predict oxacillin susceptibility for S.
pseudintermedius and S. schleiferi (10, 11).
The present study is a continuation of the work performed by CLSI to reevaluate
SOSA breakpoints. Isolates of S. capitis, S. haemolyticus, S. hominis, and S. warneri were
evaluated by reference cefoxitin and oxacillin broth microdilution (BMD) and disk
diffusion to determine the best phenotypic tests to use as surrogates for the presence
of mecA. These isolates were chosen due to their high frequency in human bloodstream
infections, ranging from 3.5 to 12% for S. capitis, 2.8 to 36.7% for S. hemolyticus, 3.0 to
18% for S. hominis, and 2.0 to 7.8% for S. warneri (1).
MATERIALS AND METHODS
Bacterial isolates. A total of 198 isolates were evaluated in this study (Table 2). Isolates included S.
capitis (n  50), S. haemolyticus (n  50), S. hominis (n  50), and S. warneri (n  48). Isolates were
collected from multiple geographic locations between 2014 and 2018 (Table 2) and were chosen to
represent a roughly even number of mecA-positive and -negative isolates for each species. The isolates
were recovered from a variety of clinical cultures, including 126 from blood cultures (64%), 25 from sterile
fluids (12.6%), 20 from skin and soft tissue (10.1%), 7 from genitourinary sources (3.5%), 6 from bone
(3.0%), 3 respiratory (1.5%), 2 ocular (1.0%), and 3 from other sources (1.5%). Isolates were identified to
the species level at each institution according to their standard operating procedures and confirmed at
Accelerate Diagnostics, Inc. (Tucson, AZ), by MALDI-TOF MS (Bruker Daltonics, Inc., Billerica, MA) and at
Washington University with Vitek MS (bioMérieux, Durham, NC).
mecA/C PCR. All isolates were evaluated for mecA and mecC by colony PCR performed from
overnight growth on tryptic soy agar with 5% sheep’s blood agar plates (BAPs; Hardy Diagnostics, Santa
Maria, CA) as previously described (12).
Antimicrobial susceptibility testing. Isolates were stored as described previously (10) and subcul-
tured twice from frozen stocks on BAPs before testing. Disk diffusion (DD) and BMD were performed as
described by CLSI (13, 14). DD was evaluated on Mueller-Hinton agar (MHA) plates obtained from 3
vendors: Remel (Lenexa, KS), Hardy Diagnostics, and BD (Sparks, MD). Disks containing 1 g oxacillin and
30 g cefoxitin (BBL, BD) were used. BMD was performed by CLSI reference, frozen-form panels
containing cation-adjusted Mueller-Hinton broth (CA-MHB) with cefoxitin or oxacillin. Oxacillin BMD tests
were supplemented with 2% NaCl. BMD panels were made by Accelerate Diagnostics, Inc. CA-MHB
samples from 3 different manufacturers (Difco [BD], BD, and Oxoid [ThermoFisher Scientific, Lenexa KS])
were evaluated on a single panel. Oxacillin and cefoxitin were tested in 2-fold dilutions at concentrations
ranging from 0.016 to 32 g/ml.
For testing, 3 to 5 isolated colonies grown overnight on a BAP at 35 to 37°C in ambient air were used
to prepare a suspension equivalent to a 0.5 McFarland standard, using a nephelometer, in 0.85% saline.
This suspension was used to inoculate all DD and BMD tests, in parallel (13, 14). DD tests were incubated
at 35 to 37°C in ambient air, and zones of inhibition were measured at 16 to 18 h for oxacillin and 24 h
for cefoxitin. BMD tests were incubated at 35 to 37°C in ambient air and read at 16 to 20 h for cefoxitin
and 24 h for oxacillin. Colony counts were performed on each inoculum by subculturing the growth
control well for each BMD panel. S. aureus ATCC 25923 and S. aureus ATCC 29213 were used as quality
controls (QCs) for DD and BMD, respectively, and quality control testing was performed each day of
testing.
PBP2a testing. PBP2a testing was performed using the Abbott PBP2a SA Culture Colony test (Abbott
Diagnostics, Inc., Scarborough, ME), according to the package insert instructions for testing S. aureus and
from the same plate used to make inocula for BMD and DD. In advance, it was agreed that isolates that
displayed a different PBP2a result versus mecA PCR result would be repeated in duplicate and that using
growth from around a cefoxitin disk and growth from a BAP would be performed, although no isolates
required induction. S. aureus ATCC 43300 and S. aureus ATCC 25923 were used as positive and negative
controls, respectively.
Data analysis. Zone diameters and MIC values were interpreted using the following breakpoints in
the CLSI M100, 29th edition, document (Table 3): S. aureus/S. lugdunensis cefoxitin disk diffusion (FOX DD
TABLE 2 Isolates evaluated in this study
Species (n isolates)
No. of isolates
mecA positive Countries of origin (n isolates)
% of isolates from
blood culture
S. capitis (50) 25 Australia, Brazil (4), Canada (6), Chile (1), Italy (1), Japan (4), South Korea (1),
Philippines (5), Poland (1), Sweden (1), Taiwan (3), Thailand (1), USA (21)
70
S. haemolyticus (50) 26 Australia (1), Belgium (1), Canada (10), France (1), Netherlands (1), South
Africa (1), Switzerland (2), USA (33)
56
S. hominis (50) 25 Canada (12), USA (38) 84
S. warneri (48) 20 Argentina (1), Australia (3), Belgium (1), Canada (7), Colombia (1), Czech
Republic (1), France (1), Germany (3), Greece (1), Israel (2), Italy (4), South
Korea (1), Kuwait (1), Philippines (2), Russia (1) South Africa (1), Spain (1),
Thailand (1), UK (2), USA (10), Venezuela (2)
44
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SAU), S. aureus/S. lugdunensis cefoxitin MIC (FOX MIC SAU), S. aureus/S. lugdunensis oxacillin MIC (OX MIC
SAU), SOSA excluding S. lugdunensis and S. pseudintermedius cefoxitin disk (FOX DD SOSA), SOSA oxacillin
MIC (OX MIC SOSA), and S. pseudintermedius/S. schleiferi/S. epidermidis oxacillin disk (OX DD SOSA) (15).
Additionally, results were evaluated with the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) 2019 oxacillin disk S. pseudintermedius breakpoint (16). Results were compared to mecA
(and mecC, although all isolates were negative) PCR as the “gold standard” for oxacillin resistance.
Categorical agreement (CA), very major errors (VMEs), and major errors (MEs) were calculated as
previously described (17). VMEs were for isolates that were mecA positive but were oxacillin or cefoxitin
susceptible. MEs were defined as those isolates that were mecA negative but were oxacillin or cefoxitin
resistant. Disk-to-MIC correlates were evaluated using dBETs software (https://dbets.shinyapps.io/
dBETS/). As each isolate was evaluated on three brands of MHA, data were pooled such that each isolate
yielded n  3 results.
RESULTS
Ninety-six isolates were positive for mecA, and 102 were negative by PCR (Table 2).
No isolates were positive for mecC. The breakdown by species included S. capitis (25
mecA positive, 25 mecA negative), S. haemolyticus (26 mecA positive, 24 mecA negative),
S. hominis (25 mecA positive, 25 mecA negative), and S. warneri (20 mecA positive, 28
mecA negative). PBP2a testing correlated 100% with the mecA PCR results, and no
induction was required for any isolate.
S. capitis. Clear separation of the mecA-positive and -negative isolates was observed
by both oxacillin and cefoxitin BMDs (see Fig. S1A and S2A in the supplemental
material). Most oxacillin MIC values for isolates with mecA were 32 g/ml (89.3%).
Only Sigma CA-MHB yielded oxacillin MICs of 32 g/ml, with 2 isolates with a MIC of
4 g/ml, 1 at 8 g/ml and 1 at 16 g/ml (Fig. S1A). Both the OX MIC SOSA and OX MIC
SAU breakpoints yielded 100% CA (Table 4). Most cefoxitin MIC values for isolates with
mecA were 32 g/ml (85.3%; Fig. S2A), whereas mecA-negative isolates in general had
a cefoxitin MIC of 2 or 4 g/ml. Overall, no statistical difference was noted between
brands of media with regard to VME or ME rates.
DD performed with a 1-g oxacillin disk similarly split the mecA-positive and
-negative isolates (see Fig. S3A in the supplemental material). Using the OX DD SOSA




Oxacillin MIC, Staphylococcus other than S. aureus and S. lugdunensis 0.25 g/ml 0.5 g/ml OX MIC SOSA
Oxacillin MIC, S. aureus/S. lugdunensis 2 g/ml 4 g/ml OX MIC SAU
Oxacillin zone diameter, S. schleiferi, S. pseudintermedius, S. epidermidis 18 mm 17 mm OX DD SOSA
Oxacillin zone diameter, EUCAST, S. pseudintermedis 20 mm 19 mm OX DD EUCAST
Cefoxitin MIC, S. aureus/S. lugdunensis 4 g/ml 8 g/ml FOX MIC SAU
Cefoxitin zone diameter, S. aureus/S. lugdunensis 22 mm 21 mm FOX DD SAU
Cefoxitin zone diameter, Staphylococcus other than S. aureus, S. lugdunensis,
S. pseudintermedius, and S. schleiferi
25 mm 24 mm FOX DD SOSA
New, oxacillin MIC breakpoint for SOSA (this study) 0.5 g/ml 1 g/ml New OX MIC SOSA
aAll breakpoints are CLSI, unless otherwise noted.
TABLE 4 Overview of phenotypic test results
Breakpoint
No. (%) of resultsa
S. capitis S. haemolyticus S. hominis S. warneri Overall
VMEs MEs VMEs MEs VMEs MEs VMEs MEs VMEs MEs
OX MIC SOSA 0/75 (0) 0/75 (0) 3/78 (3.8) 1/75 (1.4) 3/75 (4.0) 5/75 (6.7) 0/59 (0) 16/84 (19.0) 6/287 (2.1) 22/309 (7.1)
OX MIC SAU 0/75 (0) 0/75 (0) 15/78 (19.2) 0/75 (0) 3/75 (4.0) 0/75 (0) 0/59 (0) 0/84 (0) 18/287 (6.2) 0/309 (0)
OX DD SOSA 0/75 (0) 0/75 (0) 5/78 (6.4) 0/75 (0) 4/75 (5.3) 0/75 (0) 0/59 (0) 67/84 (79.8) 9/287 (3.1) 67/309 (21.7)
OX DD EUCAST 0/75 3/75 (4) 2/78 (2.6) 0/75 (0) 4/75 (5.3) 2/75 (2.7) 1/59 (1.7) 59/84 (70.2) 7/287 (2.4) 64/309 (20.7)
FOX MIC SAU 0/75 (0) 0/75 (0) 6/78 (7.7) 0/72 (0) 6/75 (8.0) 5/75 (6.7) 2/59 (3.4) 0/84 (0) 14/287 (4.9) 5/309 (1.6)
FOX DD SOSA 0/75 (0) 0/75 (0) 3/78 (3.8) 0/72 (0) 0/75 (0) 9/75 (12) 0/59 (0) 0/84 (0) 3/287 (1.0) 9/309 (2.9)
FOX DD SAU 0/75 (0) 0/75 (0) 4/78 (5.1) 0/72 (0) 3/75 (4.0) 0/75 (0) 1/59 (1.7) 0/84 (0) 8/287 (2.8) 0/309 (0)
New OX MIC SOSA 0/75 (0) 0/75 (0) 5/78 (6.4) 0/72 (0) 3/75 (4.0) 0/75 (0) 0/59 (0) 1/84 (1.2) 8/287 (2.8) 1/309 (0.3)
aBoldface values indicate errors above acceptance limits.
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breakpoint, 100% CA was seen (Table 4). Using the OX DD EUCAST breakpoint, 3/75
results represented MEs (4%; Table 4). These errors were for a single isolate with a zone
of inhibition of 18 mm on all three brands of MHA (Fig. S3A). DD performed with the
30-g cefoxitin disk yielded 100% CA using both the FOX DD SOSA and the FOX DD
SAU breakpoints (Table 4).
S. haemolyticus. No test provided good differentiation of mecA-positive from
-negative isolates of S. haemolyticus (see Fig. S1B to S4B in the supplemental material).
While over half of the oxacillin MIC values for isolates with mecA were 32 g/ml
(60.3%), 19.2% of isolates with mecA yielded oxacillin MICs of 0.25 to 1 g/ml. Isolate
WU-09, which harbored mecA, had an oxacillin MIC value of 0.25 g/ml by all three
manufacturers of media (Table 4), yielding 3.8% VMEs by the OX MIC SOSA breakpoint.
Both mecA PCR and oxacillin tests were repeated for this isolate and yielded the same
results. Additionally, a 1.4% ME rate was observed by this breakpoint (Table 4). The OX
MIC SAU breakpoint yielded 19.2% VMEs and 0% MEs (Table 4). Cefoxitin MIC values
ranged from 0.016 to 4 g/ml for mecA-negative isolates and 0.25 to 32 g/ml for
mecA-positive isolates, with substantial overlap in MICs between mecA-positive and
-negative isolates (Fig. S2B). The VME rate was 7.7% by the FOX MIC SAU breakpoint,
with no MEs (Table 4).
DD performed with 1-g oxacillin disks resulted in zones of growth inhibition
ranging from 20 to 26 mm for mecA-negative isolates and 6 to 20 mm for mecA-positive
isolates (Fig. S3). Using the OX DD SOSA breakpoint, 6.4% VMEs and 0% MEs were
observed (Table 4). Using the OX EUCAST breakpoint, 2.6% VMEs were seen and there
were no MEs. DD performed with the 30-g cefoxitin disk yielded zones of 26 to
30 mm and 6 to 28 mm for mecA-negative and -positive isolates, respectively (Fig.
S4B). Again, only VMEs were observed, at 5.1% by the FOX DD SAU and 3.8% by the FOX
DD SOSA breakpoints (Table 4).
S. hominis. The mecA-negative isolates yielded oxacillin MICs of 0.03 to 0.5 g/ml,
and mecA-positive isolates had MICs of 0.125 to 32g/ml (Fig. S1C). Three VMEs were
observed by both the OX MIC SOSA and OX MIC SAU breakpoints (Table 4), all with a
MIC of 0.125 g/ml for the same isolate (CHLA Shom 14). The only MEs were for
oxacillin BMD results interpreted by the OX MIC SOSA breakpoint (Table 4). Cefoxitin
MICs ranged from 0.25 to 8 g/ml for mecA-negative isolates and 4 to 32 g/ml for
mecA-positive isolates. The VME rate was 8.0% by the FOX MIC SAU breakpoint, with
6.7% MEs (Table 4).
Oxacillin DD resulted in zones of growth inhibition ranging from 19 to 26 mm for
mecA-negative isolates and 6 to 22 mm for mecA-positive isolates (Fig. S3C). Cefoxitin
DD results for mecA-positive isolates ranged broadly from 6 to 23 mm and from 22 to
30 mm for mecA-negative isolates (Fig. S4C). Using the OX DD SOSA breakpoint, 5.3%
VMEs and 0% MEs were seen (Table 4). Using the OX DD EUCAST breakpoint, 5.3% VMEs
and 2.6% MEs were seen (Table 4). The FOX DD SOSA breakpoint yielded 0% VMEs and
12% MEs, whereas the FOX DD SAU breakpoint yielded 4% VMEs and 0% MEs (Table 4).
S. warneri. Isolates without mecA yielded oxacillin MICs of 0.125 to 1 g/ml, and
isolates with mecA had MICs of 4 to 32g/ml (Fig. S1D). Only MEs were observed, at
19% by the OX MIC SOSA breakpoint but 0% by the OX MIC SAU breakpoint (Table 4).
Cefoxitin MICs ranged from 1 to 4 g/ml for mecA-negative isolates and 4 to 32 g/ml
for mecA-positive isolates (Fig. S2D). The VME rate was 3.4% by the FOX MIC SAU
breakpoint, with no MEs (Table 4). The two VMEs were for two different isolates,
WCM1249671 and SW-02, on two different manufacturers’ media, suggesting random
errors. However, 27% of results for isolates with mecA were at a MIC value of 8 g/ml
at the FOX MIC SAU breakpoint.
DD performed with a 1-g oxacillin disk resulted in zones of growth inhibition
ranging from 14 to 22 mm for mecA-negative isolates and 6 to 15 mm for mecA-positive
isolates. Most results (94.9%) from mecA-positive isolates generated a 6-mm zone of
inhibition (i.e., no zone). In contrast, 29.8% of mecA-negative isolates yielded a zone of
inhibition of 19 mm, with a normal distribution of zones for all isolates ranging from 14
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to 22 mm. Cefoxitin DD results for mecA-positive isolates ranged broadly from 6 to
22 mm, and the majority of mecA-negative isolates had zones of inhibition of 29 mm
(38%) or 30 mm (47.6%) (Fig. S4D). Using the OX DD SOSA breakpoint, 0% VMEs and
79.8% MEs were seen (Table 4). Using the OX EUCAST breakpoint, 0% VMEs and 70.2%
MEs were seen. CA improved with the cefoxitin disk, with 100% CA for the FOX DD
SOSA breakpoint and only 1 VME (1.7%) by the FX DD SAU breakpoint.
Evaluation of results for all species. No single MIC breakpoint performed well
across the species of SOSA evaluated (Table 4). When evaluated against CLSI criteria of
3% MEs and 1.5% VMEs (18), only the FOX DD SOSA breakpoint had an acceptable
VME rate, whereas the OX MIC SAU, FOX MIC SAU, FOX DD SOSA, and FOX DD SAU
breakpoints had acceptable ME rates. While some error rates were near acceptance
limits for an individual species, each method had at least one species for which
performance was particularly poor: OX MIC SOSA with 19% MEs with S. warneri, OX MIC
SAU with 19% VMEs for S. haemolyticus, OX DD SOSA with 80% MEs for S. warneri, FOX
MIC SAU with 8% VMEs for S. hominis, FOX DD SOSA with 12% MEs for S. hominis, and
FOX DD SAU with 5.1% VMEs for S. haemolyticus (Table 4). For each species, however,
one or more methods could be considered acceptable (Table 4).
Currently, the CLSI recommends confirmation of oxacillin MICs in the 0.5- to
2.0-g/ml range (resistant by the OX MIC SOSA breakpoints) by PBP2a or mecA
detection methods. Historically, use of cefoxitin DD was also considered acceptable. We
evaluated isolates with oxacillin VMEs or MEs for which the MIC values that generated
the errors were in this range to determine if cefoxitin DD could resolve the error. For
S. hominis, all 5 MEs were noted at a MIC of 0.5 g/ml, and all cefoxitin disk zones for
these isolates yielded zones of 22 to 23 mm (resistant by FOX DD SOSA but susceptible
by FOX DD SAU). For S. warneri isolates with MEs, oxacillin MIC values were 0.5 g/ml
(n  15) and 1 g/ml (n  1). For the 7 isolates that encompassed these 15 MEs, all disk
results obtained were susceptible by the FOX SOSA DD breakpoint. Finally, 3 VMEs and
1 ME were due to S. haemolyticus isolates with oxacillin MIC values in the 0.5- to
2.0-g/ml range. None of the 3 VMEs were resolved by cefoxitin DD, but the 1 ME was.
As such, the strategy historically proposed by CLSI performed well for resolving errors
for S. warneri, but not the other species evaluated herein.
New proposed breakpoint for oxacillin MIC and evaluation of disk correlates.
The majority (21/22 [95.5%]) of OX SOSA MIC MEs in this study occurred due to an
oxacillin MIC of 0.5 g/ml (Fig. 1). VMEs for the OX SOSA MIC breakpoint were due to
oxacillin MICs of 0.125 g/ml (n  3) and 0.25 g/ml (n  3) (Fig. 1). Adjusting the OX
SOSA susceptible MIC breakpoint from 0.25 g/ml to 0.5 g/ml resulted in an
overall reduction in MEs from 7.2% to 0.3% and an increase in VMEs from 2.1% to 2.8%,
due to two additional VMEs for the same S. haemolyticus isolate (Fig. 1 and Table 4). The
two species at this new breakpoint with unacceptable error rates were S. hominis, with
4.0% VMEs, and S. haemolyticus, with 6.4% VMEs. All three VMEs for S. hominis were for
an isolate with an oxacillin MIC of 0.125 g/ml by all three CA-MHB brands evaluated.
This isolate also yielded 1 VME by FOX MIC SAU (not shown). For S. haemolyticus, two
isolates yielded VMEs— one of these isolates yielded a VME by all breakpoints evaluated
in this study but gave a positive PBP2a result (data not shown).
In order to determine if changing the oxacillin breakpoint would impact other
species, data from prior studies were reevaluated, including evaluation of S. epidermidis
(n  100 isolates tested across three brands of media [note some isolates did not grow
on some media, yielding 291 results]), S. pseudintermedius (n  111 isolates), and S.
schleiferi (n  90 isolates). This resulted in 0% VMEs and only 3% MEs (Table 5). The ME
was for an isolate of S. epidermidis with an oxacillin MIC value of 4 g/ml but which was
mecA negative. The overall MIC distribution is shown in Fig. 1. Combined, this new
breakpoint resulted in 1.6% VMEs (8/490 mecA-positive results) and 0.9% MEs (5/562
mecA-negative results). In contrast, the 2019 CLSI OX MIC SOSA breakpoint yielded 1.2%
VMEs (6/490) and 4.5% MEs (25/562). The biggest change was for S. warneri, where the
ME rate went from 21.3% to 1.3% with this change to the breakpoint.
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Disk diffusion breakpoints are traditionally set by correlating zones of growth
inhibition to MICs, and this was attempted to see if an improved disk breakpoint could
be established with the new oxacillin MIC breakpoint. Disk correlates were evaluated
using the dBETS program, which indicated for cefoxitin a susceptible disk breakpoint of
25 mm was preferred, with a rate of 0.2% VMEs and 2.4% MEs. This is the same disk
diffusion breakpoint currently endorsed by CLSI. Similarly, a susceptible breakpoint of
18 mm was calculated for the oxacillin disk, which was associated with a 0.5% VME
rate and a 3.0% ME rate compared to the oxacillin MIC. This too is the same disk
breakpoint currently endorsed by CLSI. Manual evaluation of the disk results com-
pared to mecA PCR (as opposed to the oxacillin MIC, which is used by dBETs)
demonstrated overlap between cefoxitin zones for mecA-positive and mecA-
negative isolates of S. haemolyticus (at 27 and 28 mm; Fig. 2) and S. hominis (at 22
and 23 mm; Fig. 2). Overlap of oxacillin zones for mecA-positive and mecA-negative
FIG 1 Oxacillin MIC distribution for staphylococci evaluated in this and prior studies (Table 5). Oxacillin MICs were determined in CA-MHB plus 2% NaCl.
mecA-negative isolates are presented in panel A, and mecA-positive isolates are presented in panel B. The lower end of the MIC distribution for S.
pseudintermedius was 0.25 g/ml, and the upper end was 32 g/ml. All other species were tested across the entire oxacillin concentration range shown. The
vertical blue line represents the 2020 CLSI oxacillin breakpoint.
TABLE 5 Comparison of mecA results with oxacillin MIC values, using the M100 S30 and M100 S31 breakpoints, for isolates in the
present and prior studies
Species















S. capitis 75 75 0 0 0 0 This work
S. epidermidis 153 138 0 3 (2.0) 0 3 (2.0) 12
S. haemolyticus 72 78 3 (3.8) 1 (1.4) 5 (6.4) 1 (1.4) This work
S. hominis 84 59 3 (5.0) 5 (6.0) 3 (5.0) 0 This work
S. pseudintermedius 77 37 0 0 0 0 10
S. schleiferi 26 28 0 0 0 0 11
S. warneri 75 75 0 16 (21.3) 0 1 (1.3) This work
Overall 562 490 6 (1.2) 25 (4.4) 8 (1.6) 5 (0.89) This work
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isolates occurred for S. haemolyticus (at 20 mm), S. warneri (at 15 mm), and S.
hominis (at 20 and 22 mm) (Fig. 3; Fig. S4).
Quality control results. All results were within QC ranges, as published in the CLSI
M100 standard, 29th edition (15). S. aureus ATCC 25923 cefoxitin DD results ranged
from 23 to 28 mm (mode, 25 mm). Oxacillin DDs ranged from 18 to 21 mm (mode,
FIG 2 Cefoxitin DD distribution for staphylococci evaluated in this and prior studies (Table 5). mecA-negative isolates are presented in panel A, and
mecA-positive isolates are presented in panel B. The vertical blue line represents the current CLSI FOX DD SOSA breakpoint.
FIG 3 Oxacillin DD distribution for staphylococci evaluated in this and prior studies (Table 5). mecA-negative isolates are presented in panel A, and
mecA-positive isolates are presented in panel B. The vertical blue line represents the current CLSI OX DD SOSA breakpoint.
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19 mm). S. aureus ATCC 29213 oxacillin MIC values ranged from 0.125 to 0.5 g/ml
(mode, 0.25 g/ml) and 2 to 4 g/ml (mode, 4 g/ml).
DISCUSSION
Ideally, one MIC and/or one DD method would be established for all staphylococcal
species evaluated, enabling a more streamlined workflow for the clinical laboratory and
for device manufactures. However, each method had at least one species for which
performance was particularly poor. The CLSI AST Subcommittee agreed that imple-
mentation of species-specific breakpoints for SOSA may be unrealistic for laboratories,
given the complexity of testing and the fact that not all laboratories can accurately
perform identification of these isolates to the species level. While routine identification
of SOSA to the species level may not be indicated in all cases (e.g., likely skin microbiota
contaminant in a blood culture), we believe species identification should be attempted
for susceptibility testing when isolates are deemed clinically relevant, such as repeated
positive blood cultures or recovery from infected prostheses.
Adoption of a new breakpoint for oxacillin for these species improved performance,
both at the individual species level and generally across all isolates. Based on these
data, CLSI voted to approve a revision to the oxacillin MIC breakpoint for SOSA of
susceptible at  0.5 g/ml and resistant at 1.0 g/ml. While this new breakpoint was
still associated with errors, it provided the best correlation between mecA results across
the species evaluated to date. Disk-to-MIC correlates were performed in the present
study, which supported existing CLSI OX DD SOSA and FOX DD SOSA breakpoints. In
particular, the FOX DD SOSA performed the best among DD methods, yielding rates of
1.0% VMEs and 2.9% MEs for the isolates studied herein. However, cefoxitin tests (both
MIC and DD) yield unacceptably high rates of VMEs for S. pseudintermedius (10) and S.
schleiferi (11) and should not be used for these species.
The original 2005 CLSI breakpoint study similarly found challenges with phenotypic
detection of mecA-positive and -negative SOSA isolates. In that study, the 2019 SOSA
OX MIC breakpoint was associated with 6.8% VMEs and 28.4% MEs. Applying the new
2021 oxacillin CLSI breakpoint for species other than S. aureus and S. lugdunensis to the
2005 data set increased the VME rate to 9.1%, and the ME rate was reduced to 15.1%.
The increase in VMEs was due to 11 errors for S. hominis and 9 errors for S. epidermidis.
This is not the first time that a susceptible breakpoint of 0.5 g/ml has been
proposed for the SOSA and oxacillin. In 1995, McDonald and colleagues recommended
a breakpoint of 0.5 g/ml for oxacillin as the preferred method to detect mecA
presence for their collection of 38 isolates of S. epidermidis (19). In this study, oxacillin
testing was performed in the presence of 2% NaCl, as is the current CLSI recommen-
dation. Similarly, in 1996, Cormican and colleagues suggested an oxacillin MIC of
0.5 g/ml correlated best with the presence or absence of mecA for 55 isolates of
SOSA isolated from blood cultures (20). Furthermore, a susceptible breakpoint
of 0.5 g/ml is closer to the EUCAST-calculated epidemiological cutoff values for the
species evaluated, which are 0.5 g/ml for S. epidermidis and S. hominis and
1.0 g/ml for S. haemolyticus, S. capitis, and S. warneri (Gunnar Kahlmeter, personal
communication to R.M.H.).
There are limitations to the use of oxacillin or cefoxitin testing as a surrogate for
mecA presence among the SOSA, even when using the new oxacillin MIC breakpoint or
confirmed oxacillin or cefoxitin DD breakpoints. Every breakpoint evaluated yielded
unacceptable VME rates for S. haemolyticus, and most did as well for S. hominis (Table
4). In contrast, while not FDA cleared for use with SOSA, 100% concordance was
observed between the Abbott PBP2a test and mecA PCR. Canver and colleagues
similarly demonstrated this assay to perform well for non-S.aureus staphylococci,
including S. capitis, S. caprae, S. epidermidis, S. haemolyticus, S. hominis, S. lugdunensis,
S. pseudintermedius, S. schleiferi, S. simulans, and S. warneri (21). Adaptation of this
method for use with these species may be the preferred method for testing.
Limitations of the present study include use of only one brand of disk and testing
performed in a single, well-controlled laboratory. Additionally, no isolates harbored
Detection of mecA-Mediated Resistance in Staphylococci Journal of Clinical Microbiology
January 2021 Volume 59 Issue 1 e02290-20 jcm.asm.org 9
 on F











mecC, and so performance of phenotypic tests for isolates with that resistance factor
was not evaluated. It should be noted that the incidence of mecC among SOSA is
exceedingly low, with occasional reports of individual isolates of Staphylococcus caprae
(22), Staphylococcus xylosus (6, 23), Staphylococcus saprophyticus (24, 25), Staphylococ-
cus stepanovicii, Staphylococcus edaphicus (3), and S. warneri (22) harboring the gene.
Several isolates of Staphylococcus sciuri have been reported to harbor mecC (22). Most
laboratories perform MIC susceptibility testing using automated systems, and the
breakpoints proposed herein may not correlate with mecA results for these systems.
However, strengths of the present study include evaluation of a diverse collection of
contemporary isolates from multiple geographic regions.
In conclusion, laboratories should consider performing mecA PCR or a PBP2a test if
a penicillinase-stable penicillin, such as oxacillin, is being considered for therapy for
serious infections due to SOSA.
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